Literature DB >> 2541754

Enalapril in African patients with congestive cardiac failure.

A A Ajayi1, M O Balogun, E A Oyewo, G O Ladipo.   

Abstract

In a preliminary double-blind study in African patients with heart failure, enalapril tended to increase treadmill exercise duration relative to placebo (95% confidence interval--11.5 to 144.3 s). This was associated with a significant improvement in NYHA functional class and subjective well being (P less than 0.05 ANOVA) with a concomitant reduction in body weight (P less than 0.05 ANOVA). It significantly increased pulse pressure during forearm isometric exercise (P less than 0.05 ANOVA), but the Valsalva's manoeuvre and the orthostatic response were unchanged.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2541754      PMCID: PMC1379843          DOI: 10.1111/j.1365-2125.1989.tb05385.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  8 in total

1.  Aldosterone and its regulation during diuresis in patients with gross congestive heart failure.

Authors:  M G Nicholls; E A Espiner; R A Donald; H Hughes
Journal:  Clin Sci Mol Med       Date:  1974-10

2.  Maximal oxygen intake and nomographic assessment of functional aerobic impairment in cardiovascular disease.

Authors:  R A Bruce; F Kusumi; D Hosmer
Journal:  Am Heart J       Date:  1973-04       Impact factor: 4.749

3.  Mechanisms governing the postural response and baroreceptor abnormalities in chronic congestive heart failure: effects of acute and long-term converting-enzyme inhibition.

Authors:  R J Cody; K W Franklin; J Kluger; J H Laragh
Journal:  Circulation       Date:  1982-07       Impact factor: 29.690

4.  Effects of angiotensin converting enzyme inhibitor, perindopril, on autonomic reflexes.

Authors:  A A Ajayi; K R Lees; J L Reid
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

5.  Possible role of renin in hypertension as suggested by renin-sodium profiling and inhibition of converting enzyme.

Authors:  D B Case; J M Wallace; H J Keim; M A Weber; J E Sealey; J H Laragh
Journal:  N Engl J Med       Date:  1977-03-24       Impact factor: 91.245

6.  Plasma renin activity and plasma aldosterone concentrations in untreated Nigerians with essential hypertension.

Authors:  B Osotimehin; R T Erasmus; A O Iyun; A O Falase; Z Ahmad
Journal:  Afr J Med Med Sci       Date:  1984 Sep-Dec

7.  Effects of enalapril in heart failure: a double blind study of effects on exercise performance, renal function, hormones, and metabolic state.

Authors:  J G Cleland; H J Dargie; S G Ball; G Gillen; G P Hodsman; J J Morton; B W East; I Robertson; I Ford; J I Robertson
Journal:  Br Heart J       Date:  1985-09

8.  Severe hypotension after first dose of enalapril in heart failure.

Authors:  J G Cleland; H J Dargie; H McAlpine; S G Ball; J J Morton; J I Robertson; I Ford
Journal:  Br Med J (Clin Res Ed)       Date:  1985-11-09
  8 in total
  3 in total

1.  Heart failure: a global disease requiring a global response.

Authors:  J E Sanderson; T-f Tse
Journal:  Heart       Date:  2003-06       Impact factor: 5.994

2.  Angiotensin converting enzyme inhibition reduces proteinuria in Nigerians with chronic renal disease.

Authors:  A A Ajayi; A T Ajayi
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  The 2010 Canadian Cardiovascular Society guidelines for the diagnosis and management of heart failure update: Heart failure in ethnic minority populations, heart failure and pregnancy, disease management, and quality improvement/assurance programs.

Authors:  Jonathan G Howlett; Robert S McKelvie; Jeannine Costigan; Anique Ducharme; Estrellita Estrella-Holder; Justin A Ezekowitz; Nadia Giannetti; Haissam Haddad; George A Heckman; Anthony M Herd; Debra Isaac; Simon Kouz; Kori Leblanc; Peter Liu; Elizabeth Mann; Gordon W Moe; Eileen O'Meara; Miroslav Rajda; Samuel Siu; Paul Stolee; Elizabeth Swiggum; Shelley Zeiroth
Journal:  Can J Cardiol       Date:  2010-04       Impact factor: 5.223

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.